Table 1.
Patient characteristics
| Patient characteristics [MRI classification] | SVZ+, n = 24 (%) | SVZ–, n = 30 (%) | p value |
|---|---|---|---|
| Gender | 0.43 | ||
| Male | 17 (70.8) | 17 (56.7) | |
| Female | 7 (29.2) | 13 (43.3) | |
| Age at start RT, year | 57.9 [39–81] | 59.7 [39–81] | 0.78 |
| Karnofsky Performance Status | 0.54 | ||
| > = 80 | 14 | 21 | |
| < 80 | 10 | 9 | |
| RT dose [Gy] | 60 [40.1–60] | 60 [45–60] | 0.27 |
| Temozolomide | 0.33 | ||
| Yes | 14 (58.3) | 22 (73.3) | |
| No | 9 (37.5) | 8 (26.7) | |
| Unsure | 1 (4.2) | 0 (0) | |
| Surgery | 0.08 | ||
| Subtotal resection | 16 (66.7) | 11 (36.7) | |
| Gross total resection | 6 (25.0) | 16 (53.3) | |
| Biopsy | 2 (8.3) | 3 (10.0) | |
| MGMT promoter | 0.53 | ||
| Hypermethylated | 11 (45.8) | 10 (33.3) | |
| Hypomethylated | 12 (50.0) | 17 (56.7) | |
| Unsure | 1 (4.2) | 3 (10.0) |
Chi-squared test for categorical data, t test for continuous data [median, range]
SVZ subventricular zone, TMZ Temozolomide, MGMT O6-methylguanine-DNA methyltransferase, MGMT-STP27 classifier; TMZ+ adjuvant + concomitant Temozolomide treatment